Introduction
Chronic lymphocytic leukaemia (CLL) is a chronic lymphoproliferative disorder characterized by proliferation of clonal B lymphocytes in peripheral blood, lymph nodes, bone marrow and spleen. The median age of the patients with CLL is more than 65 years at diagnosis. In many patients, CLL is characterized by indolent clinical course and no need for any treatment for years. On the other hand, patients with Binet stage C have a median survival of only a few years. In addition to clinical stage, also cytogenetic features 1 and mutational status of immunoglobulin genes 2 have been shown to be of prognostic significance.
Although CLL is chemosensitive to alkylating agents and nucleoside analogues, there are no data indicating that this disease can be cured by conventional chemotherapy. Although fludarabine (FLU) alone 3 or combined with cyclophosphamide 4 (CY) gives high response rates in untreated patients, the disease invariably recurs and chemoresistance and infectious problems emerge in the majority of patients making further therapy difficult and responses less likely. Combinations of antibodies like alemtuzumab [5] [6] [7] and rituximab 8, 9 with chemotherapy have produced promising response rates and long-term data are awaited with interest.
As a significant number of patients with CLL are relatively young and many of them have poor prognosis, more intensive approaches including autologous and allogeneic stem cell transplantations (SCT) have been applied. [10] [11] [12] [13] Most reports on the use of ASCT in patients with CLL are from single centres [14] [15] [16] [17] with the notably exception of a prospective multicentre MRC trial. 18 We have evaluated in a nation-wide multicentre setting, the feasibility and efficacy of ASCT in patients with CLL.
Patients and methods

Patients
Altogether 72 patients with CLL received ASCT in five Finnish university hospitals between January 1995 and June 2005. Initially 35 patients (49%) were diagnosed to have Binet stage A, 29 patients (40%) Binet B and eight patients (11%) were in stage C. Cytogenetic study was initially performed in 30 patients (42%): no cytogenetic changes were observed in 10 patients, whereas a pathologic karyotype was observed in 20 patients ( þ 12 five patients, 11q-four patients, 13q-four patients, 13q14 four patients, 17p-three patients). The indications to proceed to ASCT varied during time but in early years, ASCT was mainly used for second-or third-line treatment, whereas more recently younger patients were also considered for ASCT in first complete remission (CR) or partial remission (PR) after FLU-based induction therapy.
The number of patients transplanted per centre during the study period varied from five to 29. The annual number of transplants was highest in 2001 and 2003 (13 patients in both years). The major characteristics of transplanted patients are summarized in Table 1 .
Progenitor cell mobilization and collection All patients had received debulking chemotherapy before progenitor cell mobilization. The median number of chemotherapy cycles (excluding chlorambucil) was five (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Altogether 66 patients (92%) had received FLU before progenitor cell mobilization; the median number of prior cycles with FLU was four (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Just before mobilization, the median percentage of lymphocytosis in marrow aspirate was 20%; 22 patients (30%) had X30% lymphocytes in marrow examination. ) plus G-CSF was used in additional nine patients (13%). Two patients were mobilized with G-CSF 10 mg/kg/day alone.
High-dose therapy protocols
Total body irradiation plus cyclophosphamide (TBI-CY) was the most commonly applied high-dose regimen (38 patients, 53%) followed by BEAC (N ¼ 27) and BEAM (N ¼ 6). All patients received blood progenitor cell grafts. CD34 þ selection had been performed in 44 patients (61%). Altogether 61 patients (85%) received G-CSF after the progenitor cell infusion
Response criteria
The response to conventional dose therapy as well as to high-dose therapy (HDT) was evaluated according to the National Cancer Institute criteria 19 and was based in addition to blood counts and differentials also on the evaluation bone marrow aspirate and computed tomography. For more precise response evaluation, also more sophisticated methods including fluorescent in situ hybridization, flow cytometry and polymerase chain reaction (PCR) were used during the study period in some centres. As these methods were not used in all patients, these results are not included in this report.
Complete remission was defined as absence of lymphocytosis (o4 Â 10 9 /l) in peripheral blood and marrow aspirate (o30%) with haemoglobin 4110 g/l, neutrophils 41.5 Â 10 9 /l and platelets 4100 Â 10 9 /l. Also normal spleen size and absence of lymphadenopathy were required. Partial remission was defined as at least 50% decrease in lymphadenopathy or splenomegaly, improvement of blood counts by at least 50% or haemoglobin 4110 g/l, neutrophils 41.5 Â 10 9 /l, platelets 4100 Â 10 9 /l; in addition to a decrease of 450% in the absolute lymphocyte count. All other outcomes were defined as non-response.
Definition of relapse or progression after autologous stem cell transplantation
In patients who attained a CR after ASCT, the relapse was defined as emergence of lymphocytosis with or without lymphocyte infiltration in marrow specimen. Also lymphadenopathy with a histologic verification of lymphocytic lymphoma/diffuse large B-cell lymphoma was considered a relapse. In patients who achieved only PR after ASCT, a progression was defined as 50% increase in peripheral blood lymphocytosis and/or lymphadenopathy.
Statistical analysis
All analyses were performed by using SPSS 11.0 for Windows (SPSS, Chicago, IL, USA). For univariate analysis of factors predicting outcome, the means were compared by using Mann-Whitney U-test. The w 2 test was used to compare nominal data. Progression-free survival (PFS) and overall survival (OS) were computed from the date of ASCT with Kaplan-Meier method. A relapse or progression was regarded as a competing risk for treatment-related mortality (TRM). Six patients who experienced a mobilization failure were all subsequently successfully re-mobilized.
Results
Progenitor cell mobilization and aphaeresis
Engraftment and toxicity after high-dose therapy All patients engrafted after HDT. The medians to reach neutrophils 40.5 Â 10 9 /l and platelets 420 Â 10 9 /l were 11 (8-17) and 12 (8-31) days, respectively.
Sixty-four patients (89%) experienced neutropenic fever (438 C) after ASCT. Blood cultures were positive in 29 patients (40%). The most common blood culture findings included Staphylococcus epidermidis (N ¼ 11), Streptococcus viridans (N ¼ 6) and Escherichia coli (N ¼ 5). Radiologically verified pneumonia was observed in seven patients (10%). No early (o100 days) treatment-related deaths were observed and none of the patients needed intensive care admission during ASCT. The median number of in-hospital days during HDT was 24 days (17-50); 13 patients (18%) needed hospital care for at least 4 weeks.
Outcome after autologous stem cell transplantation All patients are evaluable for response after ASCT. Altogether sixty-two patients (86%) achieved or maintained CR after ASCT, eight patients (11%) were in PR and two patients were non-responders. During the followup, myelodysplastic syndrome (MDS) has been observed in two patients (2.8%) at 10 and 19 months post-ASCT, respectively. No cases of acute myeloid leukaemia (AML) have been observed.
The projected OS for all patients at 5 years was 80% (Figure 1 ) and the median survival, 95 months (95% confidence interval (CI) 74-101). Until November 2005, 16 patients (22%) have died. Ten patients (14%) died due to progression of CLL, whereas six patients (8%) died from non-relapse reasons 101-2057 days from ASCT (infection three, glioma one, MDS one, cardiac failure one). Age at transplant (o60 vs X60 years), gender, conditioning regimen used (TBI-based vs other) or graft selection were not associated with OS in univariate analysis. Neither remission status at transplant (CR vs other status) nor the number of previous treatment lines (1 vs 41) had significant impact on OS.
With a median follow-up of 28 months (5-120 þ ) for all patients, a relapse or progression has been observed in 27 patients (37%). The projected median PFS was 48 months (95% CI 30-66) from ASCT ( Figure 2) . Age, gender, conditioning regimen used or graft selection had no significant impact on PFS in univariate analysis. Remission status at transplant had no significant impact on PFS either (Figure 3) . Patients who received ASCT after first-line treatment tended to have longer PFS than patients transplanted later during the disease course (58 vs 41 months, P ¼ 0.09). The median time from ASCT to relapse or progression was 26 months (1-81). A histological transformation was observed at relapse in four patients.
Until now, 20 patients have been treated for relapse or progression after ASCT (Table 2) . Five patients (25%) Autotransplants in CLL E Jantunen et al achieved a CR after salvage therapy and seven patients, (35%) a PR with an objective response rate of 60%. Two patients underwent allografting with reduced intensity conditioning and two additional patients are now considered for allografting. With a median follow-up of 32 months (0-50 þ ) from relapse of progression, 13 patients (48%) are still alive.
Discussion
The main findings of this multicentre nation-wide analysis were low treatment-related mortality, despite the fact that a significant percentage of the patients were X60 years at transplant, a high percentage of remissions and reasonable OS. However, there seems to be no plateau in PFS suggesting curative potential of this approach.
Previous studies of ASCT in CLL are mainly single centre based. 10, [14] [15] [16] [17] The largest experience published to date comes from Boston and includes 137 patients treated with TBI-CY plus purged BM autograft. The main findings were a 100-days TRM of 4% and no evidence of plateau in PFS. 17 The first prospective multicentre trial was performed by MRC and published recently. 18 They concluded that the procedure (TBI-CY þ blood stem cell graft) was safe (100 d mortality o2%) and induced molecular remissions in a significant proportion of patients. A rather high incidence of MDS or AML (8%) was, however, a concern. We have observed only two proven cases of MDS until now and no cases of secondary AML. Of note, no early toxic deaths were observed in our nation-wide series.
Previous studies have suggested that a significant proportion of patients with CLL may be difficult to mobilize. [20] [21] [22] We requested mobilization data only for patients who actually were transplanted. Therefore, our success rate of progenitor cell mobilization is likely to be an overestimation. However, in the majority of the patients grafts large enough to proceed to CD34 þ selection were collected. Selection of the graft may increase the risk of infectious complications. 23 Our retrospective analysis suggests that graft selection does not affect either PFS or OS. The decisive answer to the potential role of graft selection will be reached only by a randomized study utilizing surrogate markers of minimal residual disease like flow cytometry or PCR.
Indications to proceed to ASCT in this retrospective series varied. This is mainly due to the fact that there are no randomized studies evaluating the role of HDT in patients with CLL. Recently, new prognostic markers have been observed. These include in addition to clinical stage and lymphocyte doubling time also mutational status, 16, 24, 25 cytogenetics 1, 26 and most recently microRNA signatures. 27 Although these markers are useful, at present there are no prospective studies evaluating the efficacy of various treatment options in patients regarded as having poor prognosis based on these markers. The projected median PFS was 4 years in this series. Interestingly, a recent study using FLU þ CY in previously untreated patients found a median PFS of also 4 years. 4 These results are not comparable as 440% of our patients had received 2-4 lines of therapy before ASCT. It might be possible to improve the current results of ASCT further by performing prospective residual disease monitoring and using additional immunotherapy after ASCT in patients with residual disease. Given the availability of better prognostic markers and advances in the management of CLL including monoclonal antibodies like alemtuzumab [5] [6] [7] and rituximab, 8, 9 ,28 a randomized trial of ASCT against modern chemoimmunotherapy regimens seems worthwhile.
Although many patients with CLL enjoy prolonged PFS and OS after ASCT, the procedure does not seem to be curative. Therefore, some centres have moved away from ASCT to reduced-intensity conditioned (RIC) allografts. 17 Graft-versus-leukaemia effect of allogeneic SCT has been clearly shown in patients with CLL. 17, [29] [30] [31] [32] [33] Reducedintensity conditioned allografting might be the preferred approach over autografting in younger, generally fit patients with suitable donor and poor prognostic features. However, not all patients with CLL are young, have suitable donors or are fit and some of these patients might be considered for autografting.
Limited data are available on the outcome of CLL patients who progress after ASCT. Our analysis showed that a high number of responses can be obtained in relapsed patients in analogy with patients having follicular lymphoma. 34 This gives opportunity at least in some patients to consider RIC allografting at this point. In many patients, the relapse had a rather indolent course, but also some cases presenting with histologic transformation and poor prognosis were observed.
To conclude, this retrospective multicentre survey showed a low treatment-related mortality and a low risk of MDS. The outcome was in general promising although no plateau in survival curves was observed. Although ASCT seems not to be curative in patients with CLL, it is still worth considering in selected patients. Randomized trials are needed to evaluate ASCT with current nontransplant regimens and also allografting.
